Clinical trials: Patients with Advanced Solid Tumors
Advanced Solid Neoplasm
A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors
The purpose of this study is to assess the effect of multiple-dose administration of rifampin on the single dose PK of pevonedistat in adult participants with advanced solid tumors.
- Trial name
- NCT03486314
- Testing
- Pevonedistat, Rifampin, Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Solid Tumor Cancer, Lymphoma
Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas
SB-485232 will be administered as five daily intravenous (IV) infusions repeated every 28 days in adult subjects with advanced solid tumors or lymphomas.
- Trial name
- NCT00085904
- Testing
- SB-485232
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
Objectives:To evaluate the safety and tolerability of BAT8008 for injection in patients with advanced solid tumors, explore the maximum tolerated dose (MTD), and provide the recommended dose for subsequent clinical trials.
- Trial name
- NCT05620017
- Testing
- BAT8008 for Injection
- Where
- 2 sites in China
- Volunteers
- 182 people
- Sponsor
- Bio-Thera Solutions
Advanced Solid Tumors
Safety and Efficacy of LCL161 in Patients With Solid Tumors
The study will evaluate the safety of increasing doses of oral LCL161 in patients with solid tumors. It is primarily designed to evaluate the side effects and find the maximum tolerated dose of LCL161.
- Trial name
- NCT01098838
- Testing
- LCL161
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Any Solid Tumor or Lymphoma
Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma
The primary objective of this study is to determine the maximum tolerated dose (MTD) and to establish the recommended phase 2 dose of oral OSI-027 when administered via 3 schedules, namely, intermittent, weekly, and continuous in…
- Trial name
- NCT00698243
- Testing
- OSI-027
- Where
- 3 sites in United States, Belgium and 1 more
- Volunteers
- 128 people
- Sponsor
- Astellas Pharma Inc
Neoplasms
A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients
The primary objective of this study is to determine the recommended phase II dose of AVE0005 in combination with S-1 in Japanese cancer patients.
- Trial name
- NCT00479076
- Testing
- aflibercept (AVE0005), S-1
- Where
- Japan
- Volunteers
- 22 people
- Sponsor
- Sanofi
Advanced Solid Tumors
A Study of SC10914 in Patients With Advanced Solid Tumors
SC10914 is a potent selective PARP-1 and PARP-2 inhibitor. This study aims to determine the safety , tolerability , pharmacokinetic/pharmacodynamics profile of increasing doses of SC10914 when administered orally to patients with…
- Trial name
- NCT02940132
- Testing
- SC10914
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Advanced Cancer, Solid Tumor, Adult
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
This is an open-label, non-randomized, Phase 1 study to determine the safety, tolerability, and preliminary efficacy of MCLA-145 in adult patients with advanced metastatic solid tumors or B-cell lymphomas.
- Conditions
- Advanced Cancer, Solid Tumor, Adult, B-cell Lymphoma, Adult
- Trial name
- NCT03922204
- Testing
- MCLA-145, Pembrolizumab (Keytruda)
- Where
- 8 sites in United States, Belgium and 2 more
- Volunteers
- 72 people
- Sponsor
- Merus B.V.
Carcinoma, Advanced Cancer
Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients
TRX-818 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. TRX-818 is a potent anti-cancer agent in numerous human cancer cell lines.
- Trial name
- NCT02703298
- Testing
- TRX-818 capsules
- Where
- Taiwan
- Volunteers
- 19 people
- Sponsor
- TaiRx, Inc.
Carcinoid, Neuroendocrine
Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features
The primary purpose of the study is to determine if Seneca Valley Virus may be administered safely to patients with certain types of advanced cancer.
- Trial name
- NCT00314925
- Testing
- Seneca Valley Virus (biological agent)
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Neotropix
Cancer, Solid Tumor Cancer
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies.
- Conditions
- Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate
- Trial name
- NCT07424547
- Testing
- SYS6043
- Where
- 5 sites in United States
- Volunteers
- 386 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
Advanced Solid Tumors or Lymphomas
A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas
This is a phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JS019 as monotherapy in patients with advanced malignant solid tumors/lymphomas.
- Trial name
- NCT05374226
- Testing
- JS019
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Suzhou Kebo Ruijun Biotechnology Co., Ltd
Solid Tumor
Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
This study is an open-label, multicenter, Phase I/IIa, dose escalation, safety, and pharmacokinetics (PK) study of BNT142 followed by expansion cohorts in patients with Claudin 6 (CLDN6)-positive advanced tumors.
- Trial name
- NCT05262530
- Testing
- BNT142
- Where
- 18 sites in United States, Singapore and 2 more
- Volunteers
- 73 people
- Sponsor
- BioNTech SE
Solid Tumors
Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour
The main objective of the trial is to document the safety and antivascular effect of escalating doses of NGR-hTNF, from 60 mcg/sqm to 325 mcg/sqm, in patients affected by advanced or metastatic solid tumors not amenable of…
- Trial name
- NCT00878111
- Testing
- NGR-hTNF
- Where
- Italy
- Volunteers
- 48 people
- Sponsor
- AGC Biologics S.p.A.
Advanced Solid Tumors
A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers
The study is being conducted to evaluate safety, tolerability and preliminary efficacy of SHR-A1811 for Injection in combination with Fluzoparib Capsule for HER2-expressing advanced solid tumors of patients.
- Trial name
- NCT05349409
- Testing
- SHR-A1811, Fluzoparib Capsule
- Where
- 2 sites in China
- Volunteers
- 212 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Solid Tumors
Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors
This study is a Phase I clinical trial of IPI-504 in combination with docetaxel (Taxotere).The purposes of the study are to determine: the safety profile, the highest dose of IPI-504 that can be given with docetaxel without…
- Trial name
- NCT00606814
- Testing
- IPI-504, docetaxel
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Advanced or Metastatic Solid Tumors
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of HM16390, as a single agent and in combination with pembrolizumab to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced…
- Trial name
- NCT06724016
- Testing
- HM16390, pembrolizumab
- Where
- 8 sites in United States, South Korea
- Volunteers
- 292 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Locally Advanced or Metastatic Solid Tumors, NSCLC
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
- Trial name
- NCT05581004
- Testing
- Enzelkitug, Atezolizumab, Pembrolizumab
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 165 people
- Sponsor
- Genentech, Inc.
Advanced Refractory Solid Tumors
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
This is a multicenter, open-label study of CS1001 in combination with regorafenib in participants with advanced or refractory cancers.
- Trial name
- NCT04200404
- Testing
- CS1001, Regorafenib
- Where
- Australia
- Volunteers
- 19 people
- Sponsor
- CStone Pharmaceuticals
Advanced Solid Tumor, BRAF V600 Mutation
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
This is a Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in patients with BRAF V600-Mutant advanced…
- Trial name
- NCT05501912
- Testing
- ABM-1310
- Where
- 10 sites in China
- Volunteers
- 20 people
- Sponsor
- ABM Therapeutics Shanghai Company Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.